MENU
+Compare
ZNTL
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$1.18
Change
-$0.08 (-6.35%)
Capitalization
84.9M

ZNTL Zentalis Pharmaceuticals Forecast, Technical & Fundamental Analysis

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more

ZNTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ZNTL with price predictions
Jun 27, 2025

ZNTL sees MACD Histogram just turned negative

ZNTL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 20, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ZNTL moved out of overbought territory on June 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ZNTL as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ZNTL moved below its 50-day moving average on June 26, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZNTL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ZNTL broke above its upper Bollinger Band on June 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for ZNTL crossed bullishly above the 50-day moving average on June 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 129 cases where ZNTL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.287) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). ZNTL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (3.131) is also within normal values, averaging (252.247).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ZNTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZNTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ZNTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ZNTL is expected to report earnings to fall 20.15% to -53 cents per share on August 07

Zentalis Pharmaceuticals ZNTL Stock Earnings Reports
Q2'25
Est.
$-0.54
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.16
Q3'24
Beat
by $0.05
Q2'24
Missed
by $0.40
The last earnings report on May 14 showed earnings per share of -67 cents, beating the estimate of -68 cents. With 8.83M shares outstanding, the current market capitalization sits at 84.90M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BKHYY91.511.50
+1.67%
Bank Hapoalim B.M.
DIISY17.25N/A
N/A
Direct Line Insurance Group PLC
FPLSF6.32N/A
N/A
5N Plus, Inc.
ASUUF11.49N/A
N/A
A SPAC II Acquisition Corp.
MEDIF0.05N/A
-2.28%
Medipharm Labs Corporation

ZNTL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ZNTL has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ZNTL jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZNTL
1D Price
Change %
ZNTL100%
-6.35%
IDYA - ZNTL
47%
Loosely correlated
-4.13%
IMNM - ZNTL
46%
Loosely correlated
-0.23%
CRBU - ZNTL
46%
Loosely correlated
-5.19%
NGNE - ZNTL
45%
Loosely correlated
-2.47%
IPSC - ZNTL
45%
Loosely correlated
-5.74%
More